120 Results for "

PD-1/PD-L1 interaction

" in MedChemExpress (MCE) Product Catalog:
Products (120)

120 Results for "PD-1/PD-L1 interaction" in MCE Product Catalog:

Cat. No.: HY-P99345
CAS No.: 2022215-59-2
Synonyms: TSR-042; ANB-011; WBP-285

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Dostarlimab (TSR-042) is a humanized anti-PD-1 monoclonal antibody. Dostarlimab binds with high affinity to human PD-1 and competitively inhibits its interaction with its ligands, PD-L1 and PD-L2, with IC50s of 1.8 and 1.5 nM, respectively .
loading...
    loading...
Cat. No.: HY-P3139
CAS No.: 2426685-25-6
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

TPP-1 is a potent inhibitor of the PD-1/PD-L1 interaction. TPP-1 binds specifically to PD-L1 with a high affinity (KD=95 nM). TPP-1 inhibits human tumor growth in vivo via reactivating T-cell function .
loading...
    loading...
Cat. No.: HY-131183
CAS No.: 2447066-37-5
Purity:  99.52%
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

PROTAC PD-1/PD-L1 degrader-1, a PD-1/PD-L1 PROTAC based on Cereblon E3 ligand, inhibits PD-1/PD-L1 interaction with an IC50 of 39.2 nM. PROTAC PD-1/PD-L1 degrader-1 significantly restores the immunity repressed in a co-culture model of Hep3B/OS-8/hPD-L1 and CD3 T cells. PROTAC PD-1/PD-L1 degrader-1 moderately reduces the protein levels of PD-L1 in a lysosome-dependent manner .
loading...
    loading...
Cat. No.: HY-P99833
CAS No.: 2216751-26-5
Synonyms: CK-301; TG-1501

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Cosibelimab (CK-301) is a high-affinity, fully human PD-L1-blocking monoclonal antibody that binds PD-L1 and blocks its interaction with PD-1. Cosibelimab exhibits antitumor efficacy .
loading...
    loading...
Cat. No.: HY-144258
CAS No.: 2499965-12-5
Purity:  99.85%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-1/PD-L1-IN-14 (compound 17) is a bifunctional inhibitor of PD-1/PD-L1 interactions, with an IC50 of 27.8 nM. PD-1/PD-L1-IN-14 (compound 17) inhibits PD-1/PD-L1 interactions and promotes dimerization, internalization, and degradation of PD-L1 .
loading...
    loading...
Cat. No.: HY-P99573
CAS No.: 2245725-04-4
Synonyms: MGD-013

Target:  

LAG-3

Research Areas:  

Inflammation/Immunology Cancer

Tebotelimab (MGD-013) is a humanized IgG4κ bispecific PD-1/LAG-3 dual-affinity re-targeting (DART) antibody. Tebotelimab binds cell-surface expressed PD-1 and LAG-3 with EC50s of 1.65 nM and 0.41 nM in NS0 cells, respectively. Tebotelimab blocks PD-1/PD-L1, PD-1/PD-L2 and LAG-3/HLA (MHC-II) interactions and PD-1 signaling. Tebotelimab restores exhausted T-cell responses and and enhances antitumour immunity .
loading...
    loading...
Cat. No.: HY-P99641
CAS No.: 1808081-43-7

Research Areas:  

Cancer

Gilvetmab is a canine-derived anti-cPD-1 monoclonal antibody, as well as an immune activator/antitumor agent. Gilvetmab binds to canine PD-1, blocks the interaction of PD-1/PD-L1/L2, prevents immunosuppression, reactivates antitumor responses, induces tumor regression or disease stabilization, and may also trigger pseudoprogression. Gilvetmab can be used in research related to malignant melanoma and mast cell tumors .
loading...
    loading...
Cat. No.: HY-P99884
CAS No.: 2206792-50-7
Synonyms: PF-06801591

Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

Sasanlimab is a humanized IgG4 isotype anti-PD-1 antibody. Sasanlimab blocks PD-1 interaction with PD-L1/PD-L2, reverses PD-1-mediated inhibitory T-cell signaling, augments T-cell proliferation and cytokine production. Sasanlimab inhibits colon adenocarcinoma tumor growth, and accelerates graft-versus-host disease incidence via enhanced T-cell activity. Sasanlimab can be used for the research of cancer, such as bladder cancer and colon adenocarcinoma .
loading...
    loading...
Cat. No.: HY-P99544
CAS No.: 2417649-97-7
Synonyms: HBM-9167; KL-A167

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Tagitanlimab (HBM-9167) is a humanized anti-PD-L1 antibody (IgG1κ type). Tagitanlimab selectively blocks the interaction of PD-L1 and PD-1. Tagitanlimab has the potential to be studied in recurrent or metastatic nasopharyngeal carcinoma (NPC) .
loading...
    loading...
Cat. No.: HY-P99610
CAS No.: 2249882-54-8
Synonyms: BI-754091

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Ezabenlimab (BI-754091) is an anti-PD-1 mAb with binding constant Kd value of 6 nM (CHO cells). Ezabenlimab blocks the interaction of PD-1 with PD-L1 and PD-L2. Ezabenlimab increases interferon-γ secretion in T cells, and inhibits tumor growth in vivo .
loading...
    loading...
Cat. No.: HY-120402
CAS No.: 1675203-82-3
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

BMS-200 is a potent PD-1/PD-L1 interaction inhibitor with an IC50 of 80 nM. BMS-200 can induce dimerization of PD-L1 .
loading...
    loading...
Cat. No.: HY-P10950A
Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Inflammation/Immunology Cancer

PD-L1 inhibitory peptide TFA is an inhibitor targeting the PD-1/PD-L1 interaction. PD-L1 inhibitory peptide TFA inhibits the PD-1-mediated apoptosis signaling pathway, maintains the survival and activity of T cells, activates the anti-tumor effect of cytotoxic T lymphocytes, and significantly improves the survival rate of mice in fungal sepsis models. PD-L1 inhibitory peptide TFA can be used for research on sepsis, breast cancer and other related diseases, as well as immunotherapy .
loading...
    loading...
Cat. No.: HY-P3143
CAS No.: 1629655-80-6
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

BMSpep-57 is a potent and competitive macrocyclic peptide inhibitor of PD-1/PD-L1 interaction with an IC50 of 7.68 nM. BMSpep-57 binds to PD-L1 with Kds of 19 nM and 19.88 nM in MST and SPR assays, respectively. BMSpep-57 facilitates T cell function by in creasing IL-2 production in PBMCs .
loading...
    loading...
Cat. No.: HY-P9972
CAS No.: 1935694-88-4
Synonyms: PDR001

Target:  

PD-1/PD-L1 IFNAR

Research Areas:  

Cancer

Spartalizumab is a humanized PD-1 IgG4 monoclonal antibody, with a Kd of 0.83 nM for human PD-1 and a Kd of 0.93 nM for cynomolgus monkey PD-1. Spartalizumab binds to PD-1 and blocks its interaction with the ligands PD-L1 and PD-L2. Spartalizumab induces increased IFNγ release. Spartalizumab can be used in the research of anaplastic thyroid carcinoma (ATC) and neuroendocrine neoplasms (NENs) .
loading...
    loading...
Cat. No.: HY-103048A
Purity:  99.34%
Target:  

PD-1/PD-L1

Research Areas:  

Cancer

PD-1/PD-L1-IN 3 TFA, a macrocyclic peptide, is a potent and selective inhibitor of the PD-1/PD-L1 and CD80/PD-L1 interactions extracted from patent WO2014151634A1, compound No.1. PD-1/PD-L1-IN 3 TFA interferes with PD-L1 binding to PD-1 and CD80 by binding to PD-L1, with IC50s of 5.60 nM and 7.04 nM, respectively. PD-1/PD-L1-IN 3 TFA can be used for the research of various diseases, including cancer and infectious diseases .
loading...
    loading...
Cat. No.: HY-P991739

Target:  

VEGFR PD-1/PD-L1

Research Areas:  

Cancer

RC148 is a humanized IgG1 bispecific antibody targeting VEGF and PD-1. RC148 blocks PD-1-PD-L1 and VEGF-VEGFR interactions, triggers VEGF-dependent enhanced PD-1 binding, enables VEGF crosslinking, and inhibits PD-1-mediated immunosuppression. RC148 can be used for the research of metastatic gastric/gastroesophageal junction adenocarcinoma, non-small cell lung cancer, and metastatic breast cancer .
loading...
    loading...
Cat. No.: HY-131347
CAS No.: 2377916-66-8
Purity:  98.25%
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-1/PD-L1-IN-NP19 is a PD-1/PD-L1 inhibitor, with an IC50 of 12.5 nM for human PD-1/PD-L1 interaction. PD-1/PD-L1-IN-NP19 could activate the immune microenvironment in tumor, which may contribute to its antitumor effects .
loading...
    loading...
Cat. No.: HY-P99723
CAS No.: 2168561-26-8
Synonyms: BCD-135

Target:  

PD-1/PD-L1

Research Areas:  

Cancer

Manelimab (BCD-135) is a monoclonal antibody targeting PD-L1 with PD-L1 inhibitory activity. Manelimab blocks the interaction between PD-L1 and PD-1 to abrogate the immunosuppressive signals of T cells in the tumor microenvironment. Manelimab is applicable for tumor-related research .
loading...
    loading...
Cat. No.: HY-P2478
CAS No.: 2815311-61-4
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology

Human PD-L1 inhibitor V, a human PD-1 protein binding peptide with a Kd value of 3.32 μM. Human PD-L1 inhibitor V inhibit the interaction of hPD-1/hPD-L1 .
loading...
    loading...
Cat. No.: HY-P99633
CAS No.: 2342597-81-1
Synonyms: BGB-A333

Target:  

PD-1/PD-L1 Apoptosis

Research Areas:  

Cancer

Garivulimab (BGB-A333) is a humanized IgG1-variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction of PD-L1 and PD-1. Garivulimab has antitumor activity .
loading...
    loading...